<DOC>
	<DOCNO>NCT02174510</DOCNO>
	<brief_summary>To evaluate pharmacokinetic ( PK ) characteristics lurasidone single oral administration different dose healthy Chinese subject . To evaluate safety tolerability lurasidone single oral administration different dose healthy Chinese subject .</brief_summary>
	<brief_title>A Pharmacokinetic Study Lurasidone After Single Oral Administration Healthy Subjects</brief_title>
	<detailed_description>Single administration , double-blinded , placebo-controlled ( 3 subject group take placebo ) 3 dose group ( 20 mg , 40 mg 80 mg ) . There three group 20mg lurasidone placebo , 40mg lurasidone placebo 80mg lurasidone placebo . This study comprise screen period ( sign inform consent form Day -2 ) , baseline period ( Day -1 ) , treatment period ( Days 1-3 ) end study examination period ( Days 8-11 last sample collection PK evaluation ) .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<criteria>1 . After detailed explanation study objective , method procedure , anticipate efficacy , pharmacologic action , risk relevant content , subject aware relevant information relate study sign write informed consent form voluntarily . 2 . Male subject 18≤ age &lt; 40 year age signing informed consent . 3 . Subjects body weight 50.0≤ ≤ 80.0 kg BMI ( body mass index ) 19.0≤ &lt; 24.0 screen examination . 4 . Subjects able comply requirement study period , receive various physical laboratory examination per study protocol , report subjective symptom . 1 . Based examination result screen period , various physical laboratory examination perform 1 day medication ( Day1 ) administration study drug medication day , certain medical concern subject 's health status principal investigator 's study supervise physician 's opinion ( certain treatment medical observation deem necessary ) . 2 . Subjects past diabetic history . 3 . Subjects HbA1c level &gt; 6.2 % screening . 4 . Subjects history gastrointestinal operation . 5 . Because subject ' past medical history cardiovascular disease , liver disease , renal disease , endocrine disorder , digestive disease , hematologic disease , respiratory disease , mental illness , neurological disorder ( especially epilepsy convulsive disorder ) disease , subject unsuitable participate study principal investigator 's study supervise physician 's opinion . 6 . Subjects past history allergy drug . 7 . Subjects consume grapefruit food contain grapefruit ingredient 7 day medication ( Day 7 ) administration study drug medication day ( Day 1 ) . Subjects consume food contain hypericum perforatum L. ingredients 14 day medication ( Day14 ) administration study drug medication day ( Day 1 ) . 8 . Subjects take drug ( include overthecounter drug ) 7 day medication ( Day_7 ) administration study drug medication day . 9 . Regular drinker ( criteria mean daily consumption ≥2 bottle 640 mL beer Chinese liquor≥150 mL ) . 10 . Subjects use drink large amount ( criteria daily consumption &gt; 1.8 L ) caffeinecontaining beverage ( e.g . coffee , black tea , green tea , coca cola nutritional oral solution , etc ) . 11 . Subjects history drug abuse positive urine drug test . 12 . Subjects positive immunologic test result . 13 . Average amount daily smoking &gt; 20 cigarette . 14 . Subjects take study drug within 3 month ( Day_90~Day 1 ) medication . 15 . Subjects receive lurasidone orally . 16 . Subjects history blood donation 400 mL within 3 month ( Day_90~Day 1 ) medication ; 200 mL within 1 month ( Day_30~Day 1 ) medication ; donation blood component within 2 week ( Day_14~Day 1 ) medication . 17 . Subjects consume alcoholcontaining food 3 day medication 3 ( Day_3 ) administration study drug medication day . 18 . Subjects tolerate venipuncture poor peripheral venous access . 19 . Subjects unwilling abstain vigorous exercise Day_1 discharge . 20 . Other subject unsuitable participate study principal investigator 's study supervise physician 's opinion .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>pharmacokinetic</keyword>
	<keyword>lurasidone</keyword>
	<keyword>single dose</keyword>
</DOC>